Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab

PURPOSE: To determine the timing of neovascular regression after intravitreous injection of bevacizumab (Avastin(®)) 1.25 mg given as initial therapy for eyes with high-risk proliferative diabetic retinopathy (PDR) without clinically significant macular edema (CSME). PATIENTS AND METHODS: In this pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shakarchi, Faiz I, Shakarchi, Ahmed F, Al-Bayati, Shadha A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304070/
https://www.ncbi.nlm.nih.gov/pubmed/30587917
http://dx.doi.org/10.2147/OPTH.S182420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304070/
https://www.ncbi.nlm.nih.gov/pubmed/30587917
http://dx.doi.org/10.2147/OPTH.S182420

Ejemplares similares